Suppression of the @entity2339 is an accepted indicator of potential side effects from inhaled corticosteroids. Although @entity701 monitoring is frequently used to detect changes in HPA axis activity, the optimal method for identifying the subset of @entity565 @entity1 on inhaled @entity230 who experience severe @entity701 suppression of potential clinical significance has not been established. The objective of this study was to compare several methods for assessing HPA axis activity in @entity565 @entity1 taking inhaled corticosteroids. After screening, 153 @entity1 with mild to moderate @entity565 were randomly assigned to receive inhaled @entity5023 (110, 220, 330, or 440 microg bid), @entity17013 (500 microg or 1000 microg bid), or one of two control regimens ( @entity229 or placebo) for 21 days. Salivary (8 a.m.) and urinary (24-h) @entity701 determinations were compared against 22-hour area under the serum @entity701 concentration-time curve (AUC0-22 h) measured at baseline and on day 21. Comparisons were also made against 8 a.m. serum @entity701 . A significant positive correlation was found between AUC0-22 h of serum @entity701 and 8 a.m. serum @entity701 level (r = 0.5140; p = 0.0001). The AUC0-22 h of serum @entity701 was weakly correlated with 24-hour urinary @entity701 levels, both corrected (r = 0.4388; p = 0.0001) and uncorrected (r = 0.3511; p = 0.0001) for @entity1011 excretion. The 8 a.m. salivary @entity701 level correlated positively with the 8 a.m. serum @entity701 level (r = 0.5460; p = 0.0001). Salivary @entity701 was both sensitive and specific for the detection of a 50% decline in AUC0-22 h of serum @entity701 . @entity701 reductions of this magnitude have been observed following repeated use of inhaled @entity230 . Because it is noninvasive, salivary @entity701 measurement offers distinct advantages as a screening method for detecting pronounced HPA axis suppression in @entity565 @entity1 receiving corticosteroid therapy.

A comparison of methods for assessing @entity2339 activity in XXXX @entity1 treated with inhaled corticosteroids.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity17013 :: ('MESH:C007734', 'Chemical') :: ['flunisolide'] @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamic-pituitary-adrenal (HPA) axis'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['Cortisol', 'cortisol'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate']
@entity565 :: (MESH:D001249,Disease) :: ['asthma']
